Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Letters to the Editor

Prostate cancer screening

Kevin Kurator, BS, BA and Ian Jenkins, MD
Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: https://doi.org/10.3949/ccjm.88c.05002
Kevin Kurator
University of California San Diego School of Medicine, La Jolla, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Jenkins
University of California, San Diego
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editor: To make screening recommendations, including for PSA, one must consider an unbiased assessment of benefits, risks, and costs. Yet Sooriakumaran1 fails to discuss current guidelines or the harms of screening, and falsely claims a mortality benefit. Gilligan’s accompanying editorial2 fails to quantify those harms and briefly mentions the guidelines without giving the rationale to avoid screening. Both emphasize European Randomised Study of Screening for Prostate Cancer results showing a 20% relative risk reduction in disease-specific mortality.3

However, a better metric is absolute risk reduction (0.18% by our calculation), and the best metric is the absolute risk reduction for total mortality: none was noted.3 And readers of both articles would not know that for every prostate cancer death avoided, 240 men face an elevated PSA, 100 experience a cancer diagnosis, 80 of those get treatment, and 65 suffer significant harm.4

The “shared decision-making” Gilligan advocates may sound reasonable. But for PSA screening, where the risk-benefit analysis is unfavorable in most patients,4 shared decision-making is a chimera. If experts cannot fairly present the risks and benefits in the literature, much less agree on a strategy, how can lay people make an informed decision? “Punting” the decision to patients risks worsening their health outcomes at high costs, and may have profound implications for those who are unnecessarily harmed by their own decisions.5

Screening should be advised only if benefits clearly outweigh the risks. Sooriakumaran’s omission of risks and guidelines should have been addressed in Gilligan’s editorial. Together, the articles present a biased analysis of PSA screening that can cause patient harm, and the Journal should have published an article providing the case against screening.

  • Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Sooriakumaran P
    . Prostate cancer screening and the role of PSA: a UK perspective. Cleve Clin J Med 2021; 88(1)14–16. doi:10.3949/ccjm.88a.20164
    OpenUrlFREE Full Text
  2. ↵
    1. Gilligan T
    . Prostate cancer: To screen or not to screen? the question is complicated. Cleve Clin J Med 2021; 88(1):17–18. doi: https://doi.org/10.3949/ccjm.88a.20192
    OpenUrlFREE Full Text
  3. ↵
    1. Hugosson J,
    2. Roobol MJ,
    3. Månsson M, et al
    . A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol 2019; 76(1):43–51. doi:10.1016/j.eururo.2019.02.009
    OpenUrlCrossRefPubMed
  4. ↵
    Screening for Prostate Cancer; US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(18):1901–1913. doi:10.1001/jama.2018.3710
    OpenUrlCrossRefPubMed
  5. ↵
    1. Groopman J,
    2. Hartzband P
    . The power of regret. N Engl J Med 2017; 377:1507–1509. doi:10.1056/nejmp1709917
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 88 (5)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 5
1 May 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prostate cancer screening
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prostate cancer screening
Kevin Kurator, Ian Jenkins
Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: 10.3949/ccjm.88c.05002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prostate cancer screening
Kevin Kurator, Ian Jenkins
Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: 10.3949/ccjm.88c.05002
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Antiobesity drug therapy
  • Physician resistance to obesity pharmacotherapy
  • In Reply: Physician resistance to obesity pharmacotherapy
Show more Letters to the Editor

Similar Articles

Subjects

  • Preventive Care
  • Oncology
  • Men's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire